Keryx Biopharmaceuticals Inc fka KERX

[Solantey]

Today's Seeking Alpha - Market Watch

"Good news for shareholders is that Oppenheimer came out yesterday and stated that based on the closing price Friday that the shares presented an attractive entry point. The firm also stated that they had an $11/share price target on the shares and believes that the company's financing does not preclude it from selling itself but rather strengthens its position in negotiations with any potential acquirers or partners as they now have a cash reserve to hold them over."

If you're waiting for $4.00 then you might as well be waiting for $1.00.